Axsome Therapeutics Inc (AXSM) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Optimizing the distribution of neuropreparations through diversified warehouses supports the growth of share prices, and consequently, the EV/EBITDA multiple demonstrates an upward trend, with the indicator reaching 0.00. Asset stability is based on the recognition of Axsome Therapeutics (AXSM) as a leader in depression therapy. High capitalization relies on the successful commercialization of R&D projects and the release of treatments for narcolepsy.
Comprehensive metric breakdowns and analytics for axsome.com (AXSM)
- market price and analyst price targets:
- market capitalization details:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Equity Ratio Axsome Therapeutics|AXSM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Axsome Therapeutics, Inc.|AXSM - Company Cumulative Indebtedness|Debts to Book Capitalization Axsome Corp|AXSM - Company Long-Term Loans and Borrowings|Company Short-Term Debts Axsome Therapeutics|Quick Liquidity axsome.com
- business earnings and investment ratios data:
AXSM - Final Profit|Projected Future Earnings Axsome Therapeutics|AXSM - P/E Multiple|Future Price to Earnings Axsome Therapeutics|AXSM - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Axsome Corp|AXSM - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Axsome Therapeutics|AXSM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months axsome.com|AXSM - Net earnings per one share growth for the current year|Earnings growth forecast for next year Axsome Therapeutics
General company analysis:Axsome Therapeutics Inc AXSM
The EV/EBITDA multiple relates the total enterprise value, including net debt, to operating profit before taxes and depreciation, allowing for an assessment of the real value of assets regardless of the financing structure. By analyzing fluctuations in the EV/EBITDA level of Axsome Therapeutics (AXSM), an investor can track the efficiency of the company's transition to drug commercialization and the impact of neurological portfolio diversification on business capitalization.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Total Company Value to Operating Income Before Depreciation Ratio Neurocrine Corp (NBIX)|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA acadia-pharm.com|Xenon (XENE) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Viking Therapeutics Inc|SUPN (Supernus Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Catalyst Corp CPRX|Enterprise Value to EBITDA Ratio DNLI (Denali Therapeutics)|HRMY (harmonybiosciences.com) - Business Value to Operating Income Before Depreciation|Biohaven - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|AVXL: EV/EBITDA Multiple|Company Value to EBITDA ceribell.com (CBLL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prothena Corporation plc|ALEC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANNX|EV/EBITDA Multiple omeros.com (OMER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|ACIU (acimmune.com) - Company Value to Operating Income Before Depreciation Ratio|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Neumora|SCLX (Scilex Holding Co.) - Enterprise Value to EBITDA Ratio|Tevogen Bio Inc. (TVGN) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ACOG|CGTX (cogrx.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple IKT|Total Company Value to Operating Income Before Depreciation Ratio Cassava Sciences Inc|EV/EBITDA Multiple ASRT (Assertio)|COYA - Enterprise Value to EBITDA Ratio|VTGN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics Inc. OVID|ABOS: EV/EBITDA Multiple|CervoMed, Inc. (CRVO) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ATHE|Enterprise Value to Operating Income Before Depreciation CLNN (Clene Nanomedicine)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|Total Company Value to Operating Income Before Depreciation Ratio jupiterneurosciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|ANVS - Enterprise Value to EBITDA Ratio|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIFF (Firefly Neuro) - Enterprise Value to Operating Income Before Depreciation|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to EBITDA Ratio RVPH|EV/EBITDA Multiple MetaVia, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT (heliusmedical.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Company Value to EBITDA|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|ATHA - EV/EBITDA Multiple|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation ALZN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Protagenic (PTIX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI - Enterprise Value to EBITDA Ratio|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA chromocell.com|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio LBPH|MRNS (Marinus Pharma) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NKGN|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Synaptogenix Inc. (SNPX) - Company Value to EBITDA|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA: EV/EBITDA Multiple|cerevel.com (CERE) - EV/EBITDA Multiple
